Additional studies to compare the use of R-CHOP with or without bortezomib in newly diagnosed and refractory/relapsed DLBCL patients are ongoing (Supplementary Table 4) [96]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.